	PROFILE		
1	NAME	Fazleen Haslinda Mohd Hatta	
2	ACADEMIC POSITION	Senior Lecturer	
3	STATUS OF APPOINTMENT	Permanent	
4	CITIZENSHIP	Malaysian	
5	EDUCATION	PhD (Medical Science), Karolinska Institutet, Sweden – 2015; Master of Science (Pharmacogenetics), Universiti Teknologi MARA– 2009; Bachelor of Science (Hons) (Genetics and Molecular Biology), Universiti Malaya – 2004.	
6	WORKING EXPERIENCE	Senior Lecturer (DM52) Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, January 2016 – present Lecturer (DM45) Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, February 2010 – Disember 2015 Research Officer BPFK Petaling Jaya April 2005-June 2006	
7	CURRENT ACADEMIC RESPONSIBILITIES	PHC 610PHC 513PHC 612	
8	RESEARCH INTERESTS/ PROJECTS	 Drug Metabolism Genetic engineering (CRISPR/Cas) Genotyping Pharmacogenetics 	
9	PUBLICATIONS	PUBLICATIONS 1. Yusof H, Rodzi NAM, Shakir NS, Ali ABM, Kareem ZJ, Hatta FHM (2023) Development of PCR-based genotyping method for fat mass obesity-associated (FTO) gene polymorphism rs9939609. JUMMEC, eprint. 2. Mohd Hatta, F. H., Ahmad, A., & Othman, A. A. (2023). Pharmaceutical microbiology in pharmacy education: Operational process of an objective structured practical examination (OSPE) in Universiti Teknologi MARA. Electronic Journal of Medical and Educational Technologies, 16(1), em2301.	

- 3. A.A Othman, R.M. Yusoff, S.N. Nor Azam, A.Z. Ali Hassan and **F.H. Hatta** (2022) A Review on the Potential of Application of CRISPR/Cas9 Technology in CYP3A4 and CYP2D6 Genes: A Way to Move Forward in Identifying New Drug Targets ASM Sc. J., Vol. 17, 2022
- 4. HH Zulkifly, MR Muda, **FHM Hatta**, WM Kepli, S Thuraisingam, S Shaharuddin (2022) Investigating demographic and clinical characteristics of patients admitted with myocardial infarction (MI) and received percutaneous coronary intervention (PCI) in Serdang Hospital. International Journal of Cardiology, Volume 369, 36 37
- YUSOF, Hartini; OSMERA, Aimi Najwa; MOHD HATTA, Fazleen Haslinda (2021) A Review on the Association of Fat Mass Obesity Associated (FTO) Gene Marker Rs9939609 with Obesity and Body Mass Index (BMI). Buletin Sains Kesihatan, v. 5, n. 1, p. 11 - 20, ISSN 2550-1852.
- Mohd Zaid, Nur Najwa Adlina and Mohd Hatta, Fazleen Haslinda and Mohd Mutalip, Siti Syairah and Mohamed, Ruzianisra and Ahmad Noorden, Mohd Shihabuddin (2021) The roles of tumour suppressor miRNAs in liver cancer progression. International Journal of Pharmaceutical, Nutraceutical and Cosmetic Science (IJPNaCS), 4. pp. 13-32. ISSN 2682-8146
- 7. Najmi A.S.A., Halim S.N.A.A., Feizal N.N., **Hatta F.H.M.** (2021) THE CURRENT STATUS OF CYP-2D6, 2C9, 2C19 AND 3A4 INDUCED ADVERSE DRUG REACTIONS. Malaysian Journal of Biochemistry and Molecular Biology, 24 (3), pp. 15 27
- Che Omar R.N., Ismail M.I., Noorden M.S.A., Yusoff R.M., Hatta F.H (2021) Determining the Population Doubling Time of HepG2 and Huh-7 Cells and the Toxic Effect of Dimethyl Sulfoxide (DMSO). ASM Science Journal, 17, 2022
- Halim S.N.A.A., Feizal N.N., Najmi A.S.A., Omar R.N.C., Hatta F.H.M (2021) Clustered Regularly Interspaced Short Palindromic Repeat Paired Associated Protein 9 (CRISPR-Cas9) System and Its Opportunity in Medical Science-A Narrative Review. Current Applied Science and Technology, 22 (6)
- 10. Mohd Shihabuddin Ahmad Noorden, Qishtina Mizan, Nur Serene Sofia Nor Azri, Fazleen Haslinda Mohd Hatta, Amplification of purine rich site from COL4A3 gene for triple helix study in keratoconus eye disease. Abstracts from the 4th Asian Conference in

- Pharmaceutical Sciences (Asia Pharm IV): Selangor, Malaysia. 28–29 August 2019. (2019). *BMC Proceedings*, *13*(Suppl 7), 9. https://doi.org/10.1186/s12919-019-0168-7
- PHD thesis: The impact of genetics, environmental and geographical factors on the inter-individual and interethnicity differences in CYP2C9 catalised drug metabolism. (December 2015)
- 12. Hatta FH & Aklillu E. P450 (Cytochrome)
 Oxidoreductase Gene (POR) Common Variant
 (POR*28) Significantly Alters CYP2C9 Activity in
 Swedish, But Not in Korean Healthy Subjects. OMICS.
 2015 Dec;19(12):777-81. doi: 10.1089/omi.2015.0159.
 PubMed PMID: 26669712
- 13. Goktaş MT, **Hatta F**, Karaca O, Kalkisim S, Kilic L, Akdogan A, Babaoglu MO, Bozkurt A, Helldén A, Bertilsson L, Yasar U. Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation? Eur J Clin Pharmacol. 2015 Oct;71(10):1223-8. doi: 10.1007/s00228-015-1899-7. Epub 2015 Aug 2. PubMed PMID: 26233334
- 14. Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E. Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex. OMICS. 2015 Jun;19(6):346-53. doi: 10.1089/omi.2015.0022. Epub 2015 May 15. PubMed PMID: 25977991
- 15. Teh L, BANNUR Z, ZAKARIA Z, HATTA FH, SALLEH M. Single Nucleotide Polymorphism (SNPs) Analysis of Mu-opioid Receptors (OPRM1) Using Denaturing High Performance Liquid Chromatography (DHPLC) among the Intravenous Drug Users. International Journal of Pharmacy and Pharmaceutical Sciences. 2014 March 01; 6(suppl 2):281-287
- Salleh MZ, Teh LK, Lee LS, Ismet RI, Patowary A, Joshi K, Pasha A, Ahmed AZ, Janor RM, Hamzah AS, Adam A, Yusoff K, Hoh BP, Hatta FH, Ismail MI, Scaria V, Sivasubbu S. Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine. PLoS One. 2013 Aug 23;8(8):e71554. doi: 10.1371/journal.pone.0071554. eCollection 2013. PubMed PMID: 24009664; PubMed Central PMCID: PMC3751891
- 17. **Hatta FH**, Teh LK, Helldén A, Hellgren KE, Roh HK, Salleh MZ, Aklillu E, Bertilsson L. Search for the

- molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. Eur J Clin Pharmacol. 2012 Jul;68(7):1033-42. doi: 10.1007/s00228-012-1210-0. Epub 2012 Feb 1. PubMed PMID: 22294058
- 18. Teh LK, Izuddin AF, **M H FH**, Zakaria ZA, Salleh MZ. Tridimensional personalities and polymorphism of dopamine D2 receptor among heroin addicts. Biol Res Nurs. 2012 Apr;14(2):188-96. doi: 10.1177/1099800411405030. Epub 2011 May 25. PubMed PMID: 21613340
- 19. Teh LK, Langmia IM, **Fazleen Haslinda MH**, Ngow HA, Roziah MJ, Harun R, Zakaria ZA, Salleh MZ. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther. 2012 Apr;37(2):232-6. doi: 10.1111/j.1365-2710.2011.01262.x. Epub 2011 Apr 20. PubMed PMID: 21507031
- Oral presentation: L. Bertilsson & FH Hatta.
 S.25.01 Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment.
 European Neuropsychopharmacology 10/2013; 23:S147. DOI:10.1016/S0924-977X(13)70214-1

Conference paper

Unpublished paper:

Nursyamila Shamsuddin, **Fazleen Haslinda Mohd Hatta**, Mizaton Hazizul Hasan, Mohd Shihabuddin Ahmad Noorden. Evaluation of 3' untranslated region of mir497hg in transiently Expressed luciferase reporter vector for microrna-lncrna interaction study (Abstract ID: PP-LS-04)

Mohd Ikhwan Ismail, **Fazleen Haslinda MH**, Ezanee Azlina MH, Afreena Afiqah Azman, Mohd Izwan Yusof. Metabolomic Fingerprinting and Footprinting analyses for TNBC-TINCR

10	RESEARCH GRANTS	THE MOLECULAR INTERPLAY BETWEEN THE MICRORNA-130S AND CYTOKINES WITH THE EXPRESSION AND METABOLIC ACTIVITY OF DRUG METABOLISING ENZYMES. FRGS. 1 October 2023 – 30 September 2025. RM 173,200. Principal Investigator. SEQUENCING ANALYSES OF CYP450, APOLP AND PO GENES IN UCS STINGLESS BEE COLONY (KELULUT) TO DETERMINE THE HONEY QUALITY. DUCS. 1 April 2022- 30 Mac 2023. RM 19, 600. Principal Investigator. GENE EDITING ON DRUG METABOLISM CAPABLE HUMAN HEPATOCYTES. HOW WILL CRISPR/CAS9 SYSTEM DO? FRGS. 1 September 2029- 30 May 2021. Principal Investigator. GENERATION OF A CYP450 GENE KNOCKED-OUT IN VITRO DRUG METABOLISM EXPERIMENTAL MODEL: A UTILIZATION OF CRISPR/CAS9 SYSTEM. DUCS. RM 20,000. 1 November 2018- 31 October 2020. Principal Investigator. UNRAVELING THE MOLECULAR MECHANISMS ATTRIBUTING TO THE ULTRARAPID METABOLISM OF CYP2C9. FRGS. RM 77,500. 1 Mac 2010 – 14 December 2013. Principle Investigator. UNRAVELLING OF THE GENETIC POLYMORPHISM FOR ULTRARAPID METABOLISM OF PHENYTOIN. DANA PENYELIDIKAN UITM. RM 15,000. 1 January 2010- 31 December 2010. Principe Investigator. CONSULTATION GRANT Policy Paper on Intellectual Property Commercialization for The Selangor State Secretary's Office (RM40,000), 2023- Active Demand-Driven Innovation Project by Public-Private Research Network (PPRN) 2017 (RM 34,000) Concluded
11	AWARDS	WIPO Sponsorship to Skills Development and Capacity Building Conference in The Philiphines 11-15 September 2023 Title: FUNGO-TX: ADVANCED FILM-FORMING SOLUTION GOLD AWARD. IIDEX UITM 2022

12	INVOLVEMENT IN PROFESSIONAL ORGANISATIONS	Member, Human Genome Organisation (HUGO)
13		Technology Transfer Related: TNCPI Podcast (UiTM Official podcast): Produk hasil penyelidikan UiTM: Kemana boleh di bawa? (UiTM's research products: Which way to go?) (August 2023) Radio talk (UFM): How to push research innovation to commercialization (January 2022) Webinar on Product & Market Incubation (PMI) Program: What is it and how it applies to researchers in UiTM? (October 2021) Scientific Seminar: Invited speaker: Strengthening health resilience through drug research and vaccine. 3rd ICOHEX 2023, Indonesia. Invited speaker: "Integrated Approach in Medical Laboratory: Challenges & Opportunities" THE 32ND MALAYSIAN ASSOCIATION OF CLINICAL BIOCHEMISTS (MACB) 2022 CONFERENCE (VIRTUAL) Invited speaker: The pharmacogenetics of CYP2C9 and a discussion on the metabolism of losartan (October 2019), Intellectual Discourse, Atta ur Rahman Institute for Natural Products Discovery, Universiti Teknologi MARA (UiTM), Malaysia Invited speaker: Pharmacogenetics: to do or not to do? Four cases and a discussion (August 2019), AsiaPharm IV, Kuala Lumpur, Malaysia Invited speaker: Pharmacogenetics in the age of precision medicine: are we there yet? (April 2018), UMBI, Universiti Kebangsaan Malaysia Invited speaker: Novel studies on CYP2C9-mediated drug metabolism: effects of Behcet's disease and role of interethnic differences (Spring semester 2015), Karolinska Institutet, Sweden Invited speaker: Molecular genetics and environmental factors of importance for CYP2C9 activity in humans (Spring semester 2014), Karolinska Institutet, Sweden
		 Courses: Nanostring seminar series: moving from genomic discovery to translational research, Faculty of Pharmacy UiTM 13-5-2016 2nd anti-coagulation therapy workshop, Medical Faculty UiTM, 23-9-2016

		 Zebrafish workshop, Monash University 2 to 4-10-2017 5th International Postgraduate Conference on Pharmaceutical Sciences (iPoPS 18 to 20-5-2017)
		Reviewer:
		Jacobs Journal of Clinical Case Reports (2016)
		 Pharmacogenomics and Personalized Medicine (2018)
		NEVIA charity run 5-6-2016
14	COMMUNITY SERVICES	Program Penanaman Semula Pokok Nipah 21-9-2019
		Fasilitator, Program Jom, Sains Farmasi 2016-2023